Clinical and genetic characterization of patientswith BCR::ABL1 and JAK2 V617F

被引：0
|
作者：
Dangelo, V. [1 ]
Schwaab, J. [1 ]
Luebke, J. [1 ]
Fabarius, A. [1 ]
Hagen, V. [2 ]
Horing, E. [3 ]
Dengler, J. [4 ]
Metzgeroth, G. [1 ]
Kreil, S. [1 ]
Hofmann, W. K. [1 ]
Saussele, S. [1 ]
Reiter, A. [1 ]
Naumann, N. [1 ]
机构：
[1] Heidelberg Univ, Univ Hosp Mannheim, Dept Hematol & Oncol, Mannheim, Germany
[2] St Johannes Hosp Dortmund, Klin Innere Med II, Dortmund, Germany
[3] Onkologikum Stuttgart, Stuttgart, Germany
[4] Onkolog Schwerpunktpraxis Heilbronn, Heilbronn, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V893
引用
收藏
页码：266 / 266
页数：1
相关论文
共 50 条
  • [31] Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia
    de Mello Conchon, Monika Ribeiro
    Costa, Juliana Lima
    Yoshinaga Novaes, Mafalda Megumi
    Dorlhiac-Llacer, Pedro Enrique
    Fischer Chamone, Dalton de Alencar
    Bendit, Israel
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (02) : 243 - 245
  • [32] Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia
    Monika Ribeiro Mello de Conchon
    Juliana Lima Costa
    Mafalda Megumi Yoshinaga Novaes
    Pedro Enrique Dorlhiac-Llacer
    Dalton de Alencar Fischer Chamone
    Israel Bendit
    International Journal of Hematology, 2008, 88 : 243 - 245
  • [33] Development of BCR-ABL1 positive chronic myeloid leukemia in a patient with JAK2 V617F positive polycythemia vera
    Shin, S.
    Kim, J.
    Park, M.
    Song, W.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 398 - 398
  • [34] Essential Role for Stat5a/b in Myeloproliferative Neoplasms Induced by BCR-ABL1 and Jak2 V617F
    Walz, Christoph
    Lazarides, Katherine
    Patel, Nihal
    Hennighausen, Lothar
    Zaleskas, Virginia M.
    Van Etten, Richard A.
    BLOOD, 2009, 114 (22) : 132 - 132
  • [35] Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
    Antonioli, E
    Guglielmelli, P
    Pancrazzi, A
    Bogani, C
    Verrucci, M
    Ponziani, V
    Longo, G
    Bosi, A
    Vannucchi, AM
    LEUKEMIA, 2005, 19 (10) : 1847 - 1849
  • [36] Clinical characteristics of JAK2 V617F positive myeloproliferative diseases
    Andrikovics, H.
    Szilvasi, A.
    Meggyesi, N.
    Tamaska, J.
    Halm, G.
    Lueff, S.
    Nahajevszky, S.
    Egyed, M.
    Varkonyi, J.
    Mikala, G.
    Sipos, A.
    Tordai, A.
    Masszi, T.
    BLOOD REVIEWS, 2007, 21 : S124 - S124
  • [37] Clinical relevance of JAK2 (V617F) mutant allele burden
    Passamonti, Francesco
    Rumi, Elisa
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (01): : 7 - 10
  • [38] Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
    E Antonioli
    P Guglielmelli
    A Pancrazzi
    C Bogani
    M Verrucci
    V Ponziani
    G Longo
    A Bosi
    A M Vannucchi
    Leukemia, 2005, 19 : 1847 - 1849
  • [39] Aquagenic pruritus and the JAK2 V617F mutation
    Langabeer, S. E.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2019, 44 (03) : E33 - E33
  • [40] JAK2 (V617F) mutation in healthy individuals
    Passamonti, Francesco
    Rumi, Elisa
    Pietra, Daniela
    Lazzarino, Mario
    Cazzola, Mario
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (04) : 678 - 679
12345